


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled):
2. (Cancelled):
3. (Cancelled):
4. (Currently Amended): A compound of Formula I:



wherein

R^1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more $-\text{CH}_2\text{CH}_2-$ groups are replaced in each case by $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$ groups,

alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more $-\text{CH}_2\text{CH}_2-$ groups are replaced in each case by $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$ groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,

aryl having 6 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof ,

arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

R² is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;

R³ is phenpropyl, -C(O)R⁴, -(CH₂)_nC(O)R⁴, -(CH₂)_nOR⁵, -(CH₂)_nSR⁵, -(CH₂)_nSO₂R⁴, -(CH₂)_nNR⁵R⁶, -CH₂CO₂R⁵, -CH₂CONR⁶R⁵, -(CH₂)_nNR⁶SO₂R⁴, -(CH₂)_nNR⁶COR⁴, or -CH₂CONHSO₂R⁴;

R⁴ is alkyl having 1 to 12 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof

and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and

R⁵ is alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxy carbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxy carbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which

is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

R⁶ is H,

alkyl having 1 to 12 carbon atoms wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

n is 0 or 1; and

pharmaceutically acceptable salts thereof;

wherein when R^3 is $-CH_2CONR^6R^5$, R^5 is not aryl or a heterocyclic group benzyl-, thiazolyl-, benzoxazolyl-, benzthiazolyl-, benzimidazolyl-, benzothiazolyl-, tetrahydroisoquinolyl-, thiadiazolyl-, indolyl-, indanyl-, benzodioxanyl-, $-CH_2$ -benzothiazolyl-, or $-CH_2$ -pyridinyl, which in each case is substituted or unsubstituted.

5. (Cancelled):

6. (Cancelled):

7. (Cancelled):

8. (Currently Amended): A compound according to claim 4, wherein said compound is selected from:

~~(4S)-1-[N-(4,5-Dimethylthiazol-2-yl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl]-2-pyrrolidone;~~

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(3-phenylpropyl)]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(2-phenoxylethyl)]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(2-phenylthioethyl)]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-N-

phenylsulfonylaminocarbonylmethyl]-2-pyrrolidone,

~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(2-thiazolyl)aminocarbonylmethyl]-2-pyrrolidone;~~

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(2-phenylsulfonyl)ethyl]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl-1-[N-(2-

methylphenyl)sulfonylaminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(2-(4-methoxyphenyl)oxyethyl)]-2-pyrrolidone, and

(4S)-1-[N-(2-(5-Chlorobenzoxazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,

(4S)-1-[N-(2-(Benzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,

(4S)-1-[N-(2-(6-Fluorobenzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,

(4S)-1-[N-(2-(Benzimidazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

9. (Currently Amended): A compound according to claim 4, wherein said compound is selected from:

(4S)-1-[2-(3-Chlorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,

(4S)-1-[2-(4-Isopropylphenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(6-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(4-methoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

~~(4S)-1-[N-(6-Ethoxycarbonylbenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,~~
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(6-trifluoromethoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[2-(2,3-Difluorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[2-(1,2,3,4-tetrahydroisoquinolin-1-yl)carbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[1-(1,2,3,4-tetrahydroquinolin-1-yl)carbonylmethyl]-2-pyrrolidone,
~~(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,~~
 (4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[2-(6-Fluorobenzothiazol-2-yl)thioethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(6-Fluorobenzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone[,
 (4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-phenoxybenzamide,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(4-methylthiazol-2-

yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-1-[N-(6-Chlorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-methyl-N-(thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-1-[N-(Benzothiazol-2-yl)-N-(cyclopropylmethyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(Indol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(Indan-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(5-Chlorothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(4-phenylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(6-methoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]benzamide,
 (4S)-2,3-Difluoro-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]benzamide,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-methoxybenzamide,
 (4S)-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[2-(4-trifluoromethylphenoxy)ethyl]-2-pyrrolidone,
 (4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(Benzothiazol-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(4-Ethoxycarbonylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-Cyclopropylmethyl-N-(6-fluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-(2-oxo-2-phenylethyl)-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-(2-oxo-2-(4-methoxyphenyl)ethyl)-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(2,2,3,3-tetrafluorobenzo-1,4-dioxan-6-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(1,4-Benzodioxan-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-(4-Fluorophenyl)thiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4,6-Difluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Carboxythiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[2-(2-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[2-(3-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[2-(4-methoxyphenylthio)ethyl]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(5-Cyclopropylmethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(2-methylbenzyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-Methanesulfonylbenzyl)aminocarbonylmethyl]-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(4-Aminosulfonylbenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-2-yl)methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(3-methylpyridin-2-yl)methylaminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-(3-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-(2-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-(4-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(3,4-methylenedioxyphenyl)-

1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(2-thienyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(2-thienylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(2-propyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(2-pyrazinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(2-tetrahydrofuran-2-yl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-aminosulfonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-methoxyphenyloxymethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-morpholinylearbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(1-piperidinylearbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(1-pyrrolidinylearbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-(N-tertbutyloxycarbonyl)piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

~~(4S)-1-[N-(2,3-Difluorophenyl)amino]carbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl]-2-pyrrolidone, and~~

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

10. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 4 and a pharmaceutically acceptable carrier.

11. (Original): A composition of claim 10, wherein the compound is provided in a unit dosage of 0.1 - 50 mg.

Claims 12-27. (Cancelled):

28. (Cancelled):

29. (Cancelled):

30. (Previously Presented): A compound according to claim 4, wherein R^1 is optionally substituted cyclopentyl, optionally substituted phenethyl, 3-tetrahydrofuran-2-yl, CHF_2 , or cyclopropylmethyl.

31. (Previously Presented): A compound according to claim 4, wherein R^2 is CHF_2 and CH_3 .

32. (Previously Presented): A compound according to claim 4, wherein R^3 is - $(CH_2)_nOR^5$, - $(CH_2)_nSR^5$, - $(CH_2)_nSO_2R^4$, - $(CH_2)_nNR^5R^6$, - $CH_2CO_2R^5$, - $CH_2CH_2CO_2R^5$, - $CH_2CONR^6R^5$, - $(CH_2)_nNR^6SO_2R^4$, - $(CH_2)_nNR^6COR^4$, or - $CH_2CONHSO_2R^4$.

33. (Previously Presented): A compound according to claim 4, wherein R³ is CH₂CONR⁶R⁵.

34. (Cancelled):

35. (Currently Amended): A compound according to claim 4, wherein
R¹ is CHF₂ cycloalkyl, cycloalkylalkyl, heterocyclic group, or heterocyclicalkyl group;
R² is CH₃ or CHF₂; and
R³ is CH₂CONHR⁵; and
~~R⁶ is substituted or unsubstituted 1,3,4-thiadiazolyl.~~

36. (Previously Presented): A compound according to claim 35, wherein R¹ is cyclopentyl, tetrahydrofuran, cyclopropylmethyl or CHF₂.

37. (Currently Amended): A compound selected from:
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone-1-acetic acid,
(4S)-1-(N-Methoxycarbonylmethyl)-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-
2-pyrrolidone;
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-methylphenyl)-(N-methyl)aminocarbonylmethyl]-2-pyrrolidone;~~
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)-2-pyrrolidone;~~
——(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-
tetrahydrofuranyloxyphenyl)-2-pyrrolidone;
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(phenylaminocarbonylmethyl)-2-pyrrolidone;~~
——(4S)-1-[N-(3-Chlorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-
tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3-methoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-ethyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-isopropyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-cyclopropylmethyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(4-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

—(4S)-1-[N-(4-Methoxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,6-Dimethylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3,4-methylenedioxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(4-trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

38. (Cancelled):

39. (Previously Presented): A compound selected from:

(4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-trifluoromethoxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

—(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-methoxyphenyl)-N-(methyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-Methylenedioxyphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(2,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(3,5-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-(Difluoromethylene)dioxyphenyl)-N-methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone;

(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-

tetrahydrofuranyloxyphenyl] 2-pyrrolidone;

(4S)-1-[N-(3,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4R)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3S)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

—(4S)-1-[N-(4-Carboxy-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Ethanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Benzenesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-(4-Fluorobenzene)sulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-ethoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-butyloxyacetyl-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone-and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

40. (Cancelled):
41. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 37 and a pharmaceutically acceptable carrier.
42. (Cancelled):
43. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 39 and a pharmaceutically acceptable carrier.
44. (Cancelled):
45. (Currently Amended): A compound according to claim 8, wherein said compound is selected from:
- (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy)-1-(N-(phenylsulfonyl)aminocarbonylmethyl)-2-pyrrolidone; and
- ~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy)-1-(N-(2-thiazolyl)aminocarbonylmethyl)-2-pyrrolidone;~~
- (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy)-1-(N-(2-methylphenyl)sulfonylaminocarbonylmethyl)-2-pyrrolidone; ~~[[,]]~~
- ~~(4S)-1-[N-(2-(6-Fluorobenzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy)-2-pyrrolidone; and~~
- physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
46. (Currently Amended): A compound according to claim 9, wherein said compound is selected from:
- (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy]-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;
- (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-ylphenoxy]-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone; and

(4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-phenoxybenzamide;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(4-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.